U.S. Food Stock News

Earlier in April 2026, Millicom International Cellular completed a US$87.5 million reopening of its 7.375% senior notes due 2032 via a Regulation S private placement, while also entering a long-term commercial agreement with Trans Americas Fiber System to boost its subsea network capacity across Central America. This combination of new fixed-income funding and access to a next‑generation, high‑capacity subsea fiber platform could reshape Millicom’s capital allocation and infrastructure...

If you are wondering whether G-III Apparel Group at around US$31.90 is offering good value today, the key is to compare the recent share performance with what the fundamentals might justify. The stock has posted returns of 8.3% over the last 7 days, 19.7% over 30 days, 8.1% year to date and 30.0% over 1 year, with a 3 year return of 110.6% and a 5 year return of 3.8%. Recent coverage has focused on how fashion brands are positioning themselves with wholesalers and retailers. It has also...

Quest Diagnostics (DGX) opened Q1 2026 with total revenue of US$2.9 billion and basic EPS of US$2.29, setting the tone for how the new year is starting to shape up for the testing giant. Over recent quarters the company has seen revenue move from US$2.6 billion in Q1 2025 to US$2.9 billion in Q1 2026, while basic EPS shifted from US$1.97 to US$2.29. This gives investors a clear view of how the top and bottom lines are tracking through the most recent reporting stretch. With a trailing twelve...

If you are wondering whether Travel + Leisure is still good value after a strong run, the stock’s current setup puts the spotlight firmly on what you are paying for its future cash flows. The share price closed at US$76.15, with returns of 11.1% over the last 30 days and 85.2% over the past year. This can change how the market views both its growth potential and risk. Recent coverage around Travel + Leisure has focused on its position in the wider travel and consumer services space,...

If you are wondering whether Nicolet Bankshares at around US$154.86 still offers value or if most of the upside is already priced in, the recent share performance gives you a useful starting point. The stock has returned 10.9% over the last 30 days, 28.5% year to date, 36.7% over 1 year and 181.8% over 3 years. This makes the current price action important context for any valuation work. Recent coverage has focused on how regional banks are being assessed on capital strength, loan quality...

Wondering if Paylocity Holding at around US$103.60 is a bargain or a value trap? This article walks through what the current price really implies. The stock has seen a 5.8% gain over the last 7 days, but this sits against a 7.9% decline over 30 days and a 28.9% fall year to date, with a 43.4% decline over the past year and a 43.6% and 48.1% decline across 3 and 5 years respectively. Recent coverage has focused on how investors are reassessing listed software and professional services names,...

Recent performance snapshot and business mix Caesars Entertainment (CZR) has seen mixed share performance, with a small 1 day pullback following gains of about 4% over the past week and roughly 3% over the past month. Over the past 3 months, the stock shows a return of about 17%, while the 1 year total return is close to 3%. Longer horizons look weaker, with 3 year and 5 year total returns of about 35% and 73% declines respectively. The company reports annual revenue of about US$11.5b and a...

If you are wondering whether Royalty Pharma's current share price still makes sense after a strong run, the key is to look closely at what the market might be pricing in. The stock last closed at US$49.48, with returns of 1.4% over 7 days, 9.1% over 30 days, 27.3% year to date and 57.4% over the past year, which naturally raises questions about how expectations and risk perceptions are being reflected in the price. Recent attention around Royalty Pharma has largely centered on its role as a...

Sonic Automotive has acquired five additional Harley-Davidson dealerships across the US, expanding its presence in the motorcycle retail market. Harley-Davidson has introduced a new global brand platform called "RIDE", including a refreshed visual identity and a large-scale marketing campaign. For investors watching NYSE:HOG, these developments come as the stock trades at $24.27, with a 38.1% return over the past 30 days and 17.6% year to date. Over a longer horizon, a 30.1% decline over...

Wondering if Arcos Dorados Holdings at around US$9.47 is offering value or asking you to pay up for growth? This article breaks down what the current price might be telling you. The stock closed at US$9.47, with recent returns of 8.6% over 7 days, 23.3% over 30 days, 29.9% year to date, 28.9% over 1 year, 30.1% over 3 years and 97.6% over 5 years. Many readers will see this as important context when thinking about value and risk. Recent coverage has focused on Arcos Dorados Holdings as a way...

Wondering whether HNI at around US$37.30 is priced for opportunity or already reflects its potential? This article focuses squarely on what the current share price might be implying. HNI's share price sits at US$37.30 after returns of 2.9% over the past week and 9.7% over the past month. Year to date the stock shows a 12.4% decline and a 6.5% decline over the last year, set against a 60.8% gain over three years and 6.3% over five years. Recent coverage around HNI has focused on its position...

MSCI (MSCI) opened 2026 with Q1 revenue of US$850.8 million and basic EPS of US$5.54, with trailing 12 month EPS at US$17.50 and net income of about US$1.3b framing the latest print. Over the last five reported quarters, revenue has moved from US$745.8 million in Q1 2025 to US$850.8 million in Q1 2026, while quarterly basic EPS has ranged from US$3.72 to US$5.54 over the same period. This gives a clearer picture of top line scale and earnings power. With a trailing net profit margin of 40.7%...

Madison Square Garden Entertainment (MSGE) is in focus after announcing a multiyear partnership with Impossible Foods. The deal introduces branded plant-based offerings, a dedicated Impossible Grille concession and expanded in-arena promotion across Knicks and Rangers home events. See our latest analysis for Madison Square Garden Entertainment. The stock is trading at $61.42 after a 9.37% 1 month share price return and 13.03% year to date share price return. The 1 year total shareholder...

FTAI Aviation (NasdaqGS:FTAI) has launched FTAI Power, a new platform focused on repurposing retired jet engines for AI data centers. The company also announced a second structured aircraft acquisition program, expanding its approach to sourcing and financing aircraft assets. These moves signal a wider set of opportunities for FTAI Aviation beyond traditional aviation leasing and engine services. FTAI Aviation operates in aircraft leasing and engine management, and now it is stepping...

Wondering if FirstCash Holdings at around US$208 a share still offers value, or if most of the upside is already priced in. The stock has returned 2.6% over the last week, 8.3% over the past month, 32.7% year to date and 73.0% over the last year, with 3 year and 5 year returns of 125.1% and 207.7% respectively. Recent coverage has focused on FirstCash Holdings' role in consumer finance and how its pawn and retail operations fit into broader credit conditions. This helps frame expectations...

Synchrony Financial (SYF) opened 2026 with Q1 revenue of US$2,363 million and basic EPS of US$2.32, setting the tone for its latest earnings update. The company has seen revenue move from US$2,227 million in Q1 2025 to US$2,363 million in Q1 2026, while trailing twelve month EPS sits at US$10.12 on net income of US$3,517 million. This gives investors a clear read on how profitability is tracking into the new year. With margins currently framed by this earnings run rate, the quarter gives...

Wondering if Axcelis Technologies at around US$133 per share still offers value, or if most of the upside may already be reflected in the price. The stock has posted returns of 17.8% over 7 days, 57.8% over 30 days, 54.7% year to date and 195.3% over 1 year. This naturally raises questions about potential growth and shifts in perceived risk. These sharp moves sit against a backdrop of ongoing investor interest in semiconductor equipment providers and how they fit into longer term chip...

Peoples Bancorp of North Carolina (PEBK) opened 2026 with Q1 revenue of US$21.0 million and basic EPS of US$0.83, supported by trailing twelve month revenue of US$89.9 million and EPS of about US$3.75 as profitability strengthened over the past year. The bank has seen trailing EPS move from about US$3.08 to roughly US$3.75 over the last six reported quarters, while net income over the same trailing period reached US$19.9 million. This sets up the latest result against an earnings profile that...

AMC Robotics (AMCI) has just wrapped up FY 2025 with Q4 revenue of US$1.3 million and a basic EPS loss of US$0.52, while trailing twelve month figures show revenue of US$6.0 million and a basic EPS loss of US$1.36 alongside a reported 41.4% revenue decline over the year. Over the past few reported periods, quarterly revenue has ranged from US$1.3 million to US$3.2 million and basic EPS has swung between a profit of US$0.15 and a loss of US$0.52, underscoring how volatile the earnings line has...

Ciena (NYSE:CIEN) is partnering with Lightstorm to upgrade the Japan, Guam, Australia submarine cable system with advanced optical networking technology. The project focuses on the Tokyo to Sydney route, where capacity is set to be quadrupled to support heavier data traffic. The upgraded system is intended to serve cloud and AI workloads that rely on high performance international connectivity. Ciena comes into this agreement with Lightstorm after a period of very strong share price...

IDEAYA Biosciences (NasdaqGS:IDYA) has entered a clinical collaboration with AstraZeneca to study IDE849, a DLL3 TOP1 antibody drug conjugate. The program will evaluate IDE849 in combination with Imfinzi in extensive stage small cell lung cancer and other DLL3 upregulated tumors. For readers tracking IDEAYA mainly through its uveal melanoma drug darovasertib, this collaboration with AstraZeneca broadens the story. The company, trading at $31.83, has delivered a 70.9% return over the past...

Wintrust Financial (WTFC) opened 2026 with Q1 revenue of US$682.4 million and basic EPS of US$3.26, while trailing twelve month revenue stood at US$2.7 billion and EPS at US$12.10. This gives investors a clear snapshot of both the latest quarter and the broader earnings run rate. Over the past year, revenue has moved from US$2.3 billion to US$2.7 billion and trailing EPS has shifted from US$10.47 to US$12.10, setting the backdrop for how the market may read this earnings print. With a...

If you are wondering whether Calix at around US$49.58 still offers value or is starting to look stretched, the key is to look closely at what you are paying for each dollar of its future potential. The share price performance is mixed, with a 1.6% gain over the last 7 days, a 1.5% decline over 30 days, a 7.5% decline year to date, and a 31.8% return over the past year. These shifts can change how the market views both risk and opportunity. Investors have been reacting to ongoing industry...

Progress Software (PRGS) shares are in focus after the company announced a relocation and expansion of its Bengaluru office, highlighting India’s growing role in its AI work and customer facing operations. See our latest analysis for Progress Software. The Bengaluru expansion comes at a time when Progress Software’s share price return has weakened, with a 29.6% decline over 90 days and a 46.9% drop in 1 year total shareholder return. This is despite a 6.7% 7 day share price rebound that hints...